


DOCKET NO.: HER-0052/5078

COPY OF PAPERS
ORIGINALLY FILED

PATENT

GP 1646

P#5



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Carla H. Kuhner, et al.

Serial No.: 09/881,954

Group Art Unit: 1646

Filing Date: June 15, 2001

Examiner: Not Yet Assigned

For: PEPTIDES, COMPOSITIONS AND METHODS FOR THE TREATMENT
OF *BURKHOLDERIA CEPACIA*

RECEIVED

JUN 06 2002

TECH CENTER 1600/2900

DATE OF DEPOSIT: May 21, 2002
I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON
THE DATE INDICATED ABOVE AND IS ADDRESSED TO
THE ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, DC 20231.

Patrick J. Farley
TYPED NAME: Patrick J. Farley
REGISTRATION NO.: 42,524

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- ☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

200

- ☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐the first or ☐second After Final Submission, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an action that otherwise closes prosecution in the application, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and the submission fee of \$180.00 as set forth in §1.17(p).
- ☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

- ☐ In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. §120 have been made in the instant application:
- ☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. , filed .
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.


Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

This form is submitted in duplicate.

Enclosed is a copy of the PCT International Search Report dated March 19, 2002, which indicates the references to be relevant.

There are no listed references which are not in the English language.

Date: May 21, 2002


Patrick J. Farley
Registration No. 42,524

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

JUN 0 6 2002

TECH CENTER 1600/2900 Sheet 1 of 1

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. HER-0052/ 5078	Serial No. 09/881,954
		Applicant Carla H. Kuhner, et al.	
		Filing Date June 15, 2001	Group 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	23	Database WPI, "Antibacterial hexapeptide consists in order tryptophan, histidine, tryptophan, leucine, glutamine and leucine," and JP 53 028169, <i>Sun Chem. Corporation</i> , March 16, 1978 , XP002191770, 1 page, (Abstract)	
	24	Schwab, U., et al., "In vitro activities of designed antimicrobial peptides against multidrug-resistant cystic fibrosis pathogens," <i>Accession No. 131:141933 CA, American Society for Microbiology J.</i> , Antimicrob. Agents Chemother, 1999 , 43(6), 1435-1440 (1 page Abstract)	
EXAMINER		DATE CONSIDERED	